


Natural or alternative therapies for infectious diseases



Thomas V Riley

Department of Microbiology
The University of Western Australia
The WA Centre for Pathology &
Medical Research







Alternative therapies for infectious diseases

- Probiotic therapy

Probiotic therapy uses a live microbial food supplement to beneficially affect the host.

- Naturally-occurring antimicrobial agents

Phytomedicines (plant-based remedies in the form of teas, extracts and oils) are a multimillion dollar industry worldwide.

- Bacteriophage therapy

Bacterial viruses that are making a comeback.

Probiotic therapy

- Uses supposedly non-pathogens
- Both bacteria and yeasts have been used
- vaginal candidiasis
- bacterial vaginosis
- urinary tract infections
- diarrhoeal diseases

How do probiotics work?

- Antagonism through production of inhibitory substances
- Competitive inhibition for sites/nutrients
- Immunomodulation of the host
- Inhibition of toxins

Filho-Lima *et al.* (2000) *J Appl Microbiol* 88: 365-370

Lactobacillus GG

- *Lactobacillus casei* var *ramnosus*
- Extensively studied
- Reduces traveller's diarrhoea
- Reduces rotavirus diarrhoea
- Reduces the severity of diarrhoea in childcare centres
- Has lots of non-specific effects
- Available commercially

Urogenital tract infections

Lactobacilli

- Depleted lactobacilli may lead to:
 - Increased UTI
 - Bacterial vaginosis
 - *Candida* vaginitis
 - Post-antibiotic infections
- Lactobacilli susceptible to nonoxynol-9

Urogenital tract infections

Lactobacilli

- Possible mechanisms of control
 - Production of antimicrobial substances
 - Lactic acid production
 - Hydrogen peroxide production
 - Bacteriocin-like substances
 - Formation of a barrier population

Urogenital tract infections

Lactobacilli (*L.casei*, *L.crispatus*)

- Characteristics required as a probiotic
 - Ease of cultivation and non-pathogenicity
 - Adhesion
 - Population stability
- Preparations currently available
- Delivery systems need work

Diarrhoeal diseases

- *Clostridium difficile*-associated diarrhoea
- Can be difficult and expensive to treat
- Relapse rate around 20%
- Various probiotic treatment regimens
 - Oral *Lactobacillus* GG
 - Rectal administration of faecal enemas
 - Non-toxigenic *C.difficile*
 - *Enterococcus* SF68

Effect of LGG yoghurt on *Clostridium difficile*-associated diarrhoea

	Diarrhoea	No diarrhoea
Yoghurt	1 (No <i>C.difficile</i>)	15
No yoghurt	7 (2 <i>C.difficile</i>)	10

Fisher's exact test, $P = 0.02$

Effect of LGG yoghurt on *Clostridium difficile*-associated diarrhoea

Month	Specimens	No.positive	% positive
November	77	10	12.9
December	127	15	11.8*
January	133	7	5.2*
February	59	4	6.7


*P < 0.05

Saccharomyces boulardii

- A nonpathogenic yeast that:
 - Survives gastric acid
 - Multiplies to high numbers
 - But need to keep taking
 - Not inhibited by antibiotics
 - Does not affect normal flora
 - Prevents CDAD in animals
- Is it effective in preventing human CDAD?

Human studies with *S.boulardii*

- 11 of 13 patients with recurrent CDAD cured (Surawicz *et al.* 1989)
- *S.boulardii* plus antibiotics resulted in a significantly reduced risk of recurrence of CDAD versus antibiotics and placebo (McFarland *et al.* 1994)
- Significant reduction in AAD (McFarland *et al.* 1995) versus none (Lewis *et al.* 1998)

- 
- No help with preventing primary infections
 - But may help prevent recurrences
 - Most of the expense related to CDAD is probably associated with recurrences.

How does *S.boulardii* work?

- *S.boulardii* secretes a protease which:
 - digests toxin A and B molecules
 - digests toxin A and B receptors on brush border membrane
- (Castagliuolo *et al.* 1996, 1999)

Experiences with *S.boulardii*

- So far we've treated 25 patients with recurrent CDAD
- All elderly
- Given vancomycin for 7 days plus lyophilised *S.boulardii* (500 mg bd) concurrently and then continuing for another 3 weeks
- 24 of the 25 patients cured
- 1 patient non-compliant!

Conclusions on *S.boulardii*

- Clear evidence that “*S.boulardii*” is a useful adjunctive agent
- In vitro evidence to explain such an effect
- The effect appears to be strain (?species) specific
- Further in vitro and clinical work warranted

Naturally-occurring antimicrobials

- garlic
- qinghaosu
- cranberries
- honey
- tea tree oil
- “Dysentery bush”
(*Grewia retusifolia*)
- “Jelly leaf”
(*Sida rhombifolia*)
- “Quinine tree”
(*Alstonia constricta*)
- “Caustic bush”
(*Sarcostemma australe*)

Garlic




Garlic (*Allium sativum*)

- First used in 3000BC by the Sumerians
- Juice used by French and English in W W I to treat infected wounds
- Antimicrobial properties attributed to allin which converts to allicin
- Di-allyl tri- & tetrasulphides very potent
- Active against many bacteria and fungi including dermatophytes

Qinghaosu



The fresh leaves



Qinghaosu

- Extract of *Artemisia annua* first described in China for malaria in 1596
- Derivatives made chemically of parent compound artemisinin
- An oral form (artesunate) gives cure rates of around 90%
- When combined with mefloquine cure rates increase to 100%

(Looareesuwan *et al.* *Lancet* 1992; 339: 821-824)

The Cranberries



Cranberries



Juice
10 oz. of 27 %
juice cocktail

=



Fresh
1-½ cups fresh
or frozen

=



Dried
1 oz.
sweetened

=



Sauce
½ cup



Cranberries

- American folk remedy for UTI
- In vitro studies show that CJ diminishes expression of fimbriae and binding of *E.coli* to cells (Zafriri *et al.* AAC 1989; 33: 92-98)
- A recent prospective, randomised, placebo-controlled trial showed a 50% reduction in incidence of bacteriuria

(Avorn *et al.* JAMA 1994 271: 751-754)

Honey

- Long recorded history of use
- Antibacterial activity against a range of organisms: *E.coli*, *Pseudomonas*, enterococci and *H.pylori*
- Activity attributed to high osmolarity, low pH, presence of H_2O_2 but there is something else
- Renewed interest in wound care







Tea tree oil

www.meddent.uwa.edu.au/teatree







Tea tree oil

- leaves of Australian plant *Melaleuca alternifolia*
- extracted by steam distillation
- leaves yield approx 1-2% dry weight
- clear/pale yellow oil
- viscous volatile lipophilic liquid
- distinct odour

Components of tea tree oil

- approximately 100 components
- compositional levels may vary
- partly regulated by the international standard for 'tea tree' oil (ISO 4730)
- 7 components comprise 80-90% of the whole oil

Components of tea tree oil

- terpinen-4-ol
- 1,8-cineole
- δ -terpineol
- α -terpinene
- δ -terpinene
- terpinolene
- p -cymene
- linalool

MICs (%) of TTO against skin flora


Organism (no.)	MIC ₉₀	MBC ₉₀	
<i>Corynebacterium</i> spp.(10)	2	2	commensal
<i>Micrococcus</i> spp. (11)	0.5	6	
CNS (60)	1	6	
<i>E. coli</i> (113)	0.25	0.25	transient
<i>K. pneumoniae</i> (14)	0.25	0.25	
<i>S. marcescens</i> (11)	0.25	0.25	
<i>Staph. aureus</i> (163)	0.5	2	

Germ tube formation

- Germ tubes may be important in the pathogenesis of candidal disease
 - ↑ adherence and penetration of epithelial cells
- Tea tree oil is potentially useful in the treatment of superficial candida infections

Aim: To determine whether tea tree oil inhibits germ tube formation in *C. albicans*

Germ tube formation by *C. albicans* 10231 in the presence of tea tree oil



In vivo tea tree oil studies

- acne trial (Bassett *et al.*, 1990)
 - tto gel as efficacious as benzoyl peroxide in the treatment of acne, fewer side effects
- tinea trial (Tong *et al.*, 1992)
 - symptomatic relief only
- onychomycosis trial (Buck *et al.*, 1994)
 - tea tree oil as efficacious as clotrimazole
- oral candidiasis (Jandourek *et al.*, 1998)
 - mycological and symptomatic response

Cold sores

- caused by Herpes simplex viruses
 - produces lesions on/around lip
 - usually HSV1, sometimes HSV2
 - causes recurrent infections
 - multiple episodes per year
 - episodes last 1-2 weeks
- few current treatments (Zovirax)
 - limited evidence

Cold sore pilot study

- pilot study Sept 1999 - March 2000
 - randomised
 - single-blind
 - placebo-controlled
 - 20 patients

Cold sore pilot study

- patient presents when cold sore first develops
- apply ointment 5 times daily
 - 6% tea tree oil gel
 - placebo gel
- keep diary
- seen daily until completely healed (approx 1-2 weeks)
- specimen taken daily (except Sun)

Cold sore pilot study results

	Treatment	
Time (days) to:	TTO (n=9)	placebo (n=9)
crust	3.7	4.6
re-epithelialisation	9.9	12.0
PCR negative	6.5	7.9

no significant differences between treatments
due to small sample size

TEATREE RD



Other clinical studies completed, underway or planned


- Mouthwash for *Candida*
- Impetigo
- Bacterial vaginosis
- *Candida* vaginitis
- Ulcers
- Several MRSA decolonisation studies

Bacteriophage therapy

D'Herelle/Twort




Bacteriophage therapy



- Ignored apart from Soviet bloc countries
- Reports in 1970s/80s of treating SA infections
- In UK, phage used to treat diarrhoeal disease in animals due to *E.coli*
- Phages for *Acinetobacter* and *Pseudomonas* infections successful

Bacteriophage therapy



- Bioavailability
- Some MRSA less susceptible to phage
- Safety concerns
 - Phage antibody
 - Toxins in preparations
 - Lysogenic conversion
- Development of resistance

Bacteriophage therapy



- Phages applied either topically, s/c, or via irrigation or drains



Conclusions

- “Natural” therapies are viewed favourably by patients
- Less side effects than antibiotics
- Some problems relating to quality
- Lack of good data
- Worthwhile exploring further as adjunctive or replacement therapy